Back to results
US 2022/0177599 A1Published application
Dual chimeric antigen receptor targeting epcam and icam-1
AssigneeAffyImmune Therapeutics, Inc.
InventorMoonsoo JIN
Life of this patent
Estimating the term…
Abstract
The present invention relates to low affinity dual chimeric antigen receptors (CARs), which provide cytotoxicity against heterogenous tumors and alleviate on-target, off-tumor toxicities. The dual CARs are constructed to have two binding domains bearing reduced affinities of 50 nM to 50 μM, one of which is the inserted or I domain of the αL subunit of Lymphocyte function-associated antigen-1, and the other one is scFv of EpCAM antibody. The dual CAR T cells of the present invention provide enhanced anti-tumor activity and reduced rate of tumor relapse.
Claims18
A dual chimeric antigen receptor (CAR) comprising:
- (a) a single-chain variable fragment (scFv) against EpCAM,
- (b) an I domain of the αL subunit of human lymphocyte function-associated antigen-1 that binds to ICAM-1,
- (c) at least one transmembrane domain,
- (d) at least one co-stimulatory domains, and
- (iv) at least one activating domain.
2 more elements
Dependencies are inferred from the claim text.